Enabling delivery of affordable medications for healthcare plans and individuals

  • Portsmouth, NH
  • Healthcare | Services
The mission is to be the premier provider of internationally sourced affordable medications for healthcare plans and individuals. Care2Care International will be known as a brand that builds lasting relationships with customers and plan members, and consistently delivers exceptional value.


Raised from investors
Debt / Equity
Offering Type
Price per Share
Pre-Money Valuation
Offering Minimum
Conv. Notes
Min. Investment
Reg CF
Offering placeholder here
Offering Maximum

This Reg CF Offering is made available through TycoonoInvest Portal LLC

Why Invest in Care2Care?


        • Well-established, far-reaching ecosystem to become the premier provider of internationally sourced affordable medications for a vast market of self-insured healthcare plans and under-insured individuals.


        • Provides a simple solution for procuring US FDA-approved medications delivering huge savings for hundreds of costly prescription drugs.


        • Focus on 2-5% of the insured population, accounting for over 50% of pharmacy plan costs and delivering savings of up to 80%.


        • Highly experienced team that partners and collaborates with experts of the healthcare ecosystem who are dedicated to delivering effective and affordable healthcare.


        • Multiple revenue stream business model with estimated Year 3 net operating income of $680K on total revenue of $1.1 million.

Value Proposition


value prop

Market Potential



Business Model

  • We partner with international licensed pharmacies to allow patients access to affordable prescription drugs.

  • Drugs represent 25% of a healthcare plan cost: to address the issue comprehensively we signed a strategic partnership with an innovative, transparent, 100% pass-through PBM.

  • This new service called Care2Care Choice Rx™ will allow C2C to reach out to employers with a full pharmacy solution achieving the lowest net cost reference price.

  • At stake for the employer: a potential cost reduction of 40%+ of Rx expenditures, meaning 10%+ of total health care plan spending.

  • We offer our programs to employers, benefits consultants, and plan administrators.

  • We charge a performance fee based on the amount of savings, on average about 10% of the acquisition price of the medication provided.
  • To target small and mid-size self-insured employers, we will invest in our own sales force.




General Information in the market

  • International drug sourcing is a healthcare benefit sector in its infancy.

  • There are only a few, rather “secretive” competitors.

  • Prices and ancillary services are not published.

  • Sourcing is key, in price level and volume capacity:

    • Competitors are sourcing in small English-speaking countries, mainly Canada, New Zealand, and Australia.

    • Care2care has begun to build a network in the EU, a huge market where prices are lower than in Canada.

  • Care2care is a member of a group of more than 800 benefits professionals who decided to change the rules of the sector, offering:

    • control of prices and margins, and

    • transparency of information




Management Team



André Wencker, Founder and CEO

André held multiple leadership and executive positions as CFO, GM, and CEO in the health insurance industry, both mandatory and supplemental, and in the retirement pension sector: Gras Savoye (largest French insurance broker), Maaf-Santé, CAMAC, and MGC Mutual.

He is the owner and Principal at AWA Conseil, a Business consulting firm he started in 2002 in the French supplemental health insurance sector, more specifically focusing on business development and innovation.

André is a graduate from HEC Paris (#1 Business School in Europe), with an MS in Business Administration, holds an Executive Health MBA EHESP and ESCP Europe – 2013 (Comparative study and analysis of primary health systems in the developed world), and is a member of the French Institute of Actuaries since 1995.

André is a member of the board of the not-for-profit Foundation FORCE, aimed at financing medical research in the Eastern region of France.

André is CEO of Care2Care SARL, a company organized under the laws of France, which is the main shareholder of record for this Company, Care2Care International LLC, a New Hampshire limited liability company.


Pascal Orliac, Co-Founder and Chief  Marketing Officer

Pascal is a Lecturer at the University of New Hampshire’s Peter T. Paul College of Business and Economics, and a member of the Board of Advisors of Pragmatic Consulting Inc.

As Global VPHR of Goss International, Pascal directed the design and implementation of HR strategies and practices in the Americas, Europe, and Asia-Pacific. He started his career as an entrepreneur and was co-founder of two start-up companies in the Tourism industry in France. Pascal holds an MBA from HEC Paris, France, and a Bachelor’s degree in Management Sciences with concentrations in Marketing and Finance from Paris University.

He is a member of the Board of Directors of the Birchtree Center, a non-profit school helping children and youth with autism grow and flourish in their families and communities.




Use of Funds










Offering Summary

Company: Care2Care International LLC

Address: 70 Meadow Road, Portsmouth, NH 03801

Minimum Investment: $200

Offering Minimum: $10,000

Offering Maximum: $400,000



Offering Type: Debt/Equity

Security: Convertible Notes

Price per Note: $1.00

Minimum Number of Notes Offered: 10,000

Maximum Number of Notes Offered: 400,000

Pre-Money Valuation: $1,539,394


A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Follow Care2Care to be notified of any future updates!

Review for Care2Care

Leave a Reply